tocilizumab [RoActemra/Actemra]
WP18663
Phase 3 small_molecule completed
Quick answer
tocilizumab [RoActemra/Actemra] for Rheumatoid Arthritis is a Phase 3 program (small_molecule) at Hoffmann-La Roche with 3 ClinicalTrials.gov record(s).
Program details
- Company
- Hoffmann-La Roche
- Indication
- Rheumatoid Arthritis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed